Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CARE-MI

Financiado

Cerrado

CARDIO REPAIR EUROPEAN MULTIDISCIPLINARY INITIATIVE

Ischemic Heart Disease (IHD) is the biggest single cause of death in Europe and in the developed world. Angioplasty and stents are successful in re-establishing perfusion of ischemic myocardium and have helped to reduce early mort... ver más

30/09/2015

CENTRO NACIONAL DE...

15M€

Presupuesto del proyecto: 15M€

Líder del proyecto

CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASC... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 28M€

Fecha límite participación Sin fecha límite de participación.

Ver 14 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-09-30 No tenemos la información de la convocatoria

0% 76% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

14 Participantes

CENTRO NACIONAL DE INVESTIGA...

0.00€ | Lider

KINGS COLLEGE LONDON

N.D. | Participante

KU Leuven

N.D. | Participante

IBET

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RTC-2016-4911-1 Desarrollo clínico de una terapia celular para reparación ca... 641K€ Cerrado

CARDIOCELL Development of cardiomyocyte replacement strategy for the cl... 4M€ Cerrado

VASC-GEN Endoglin Mediated Vascular Regeneration to Promote Heart Rep... 231K€ Cerrado

EuroXpand EUROpean clinical validation of a new ex vivo eXpanded stem... 5M€ Cerrado

EUIN2013-50760 CARDIAC REGENERATION TECHNOLOGY 25K€ Cerrado

EUIN2017-89173 CREACION DE MICROENTORNOS PARA LA REGENERACION CARDIACA IN V... 6K€ Cerrado

Líder del proyecto

CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASC... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 28M€

Presupuesto del proyecto 15M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Ischemic Heart Disease (IHD) is the biggest single cause of death in Europe and in the developed world. Angioplasty and stents are successful in re-establishing perfusion of ischemic myocardium and have helped to reduce early mortality after acute myocardial infarction (AMI). However damaged tissue is not recovered and, therefore, this is always followed by cardiac remodelling and Chronic Heart Failure (CHF). CHF is a terminal disease with an annual mortality rate of ~18% with no cure besides heart transplantation, only available to a minority of patients. Autologous cell therapy has been proposed as a solution and clinically tested but has proven marginally effective at best. Its cost and the complexity of clinical procedures make it unsuitable for treating the large number of patients that need affordable and readily available products to treat the acute phase of the disease. Moreover, most of these approaches are predicated on the outmoded concept that the adult human myocardium lacks regenerative capacity. Recent findings show that adult myocardium harbours a population of resident pluripotent cells with the characteristics of true cardiac stem cells (CSC) able to regenerate contractile myocardium. This opens novel therapeutic avenues capable of producing real anatomical and functional regeneration. The CARE-MI proposal addresses the clinical implementation of this recent paradigmatic change. We will clinically test and further develop myocardial regenerative therapies based on the in situ activation, multiplication and differentiation of the endogenous CSCs with the aim to provide therapies that are: a)Affordable, in terms of the production costs of the medicinal product b)Readily and widely available, implying that the product may be easily stored and readied for application at all times at minimum cost. c)Easy to apply and compatible with current clinical standard of care for AMI, including the widespread use of PTCA interventions

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores